A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Exclusion Criteria7

• Creatinine clearance \<30 mL/min.
• Platelet count \<75,000/μL, absolute neutrophil count \<1,000/μL, or hemoglobin \<60 g/L at screening.
• ALT or AST \>3× ULN, or bilirubin \>2× ULN.
• Known severe cardiac conditions, including NYHA class III/IV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled/severe cardiovascular diseases, including prior cerebrovascular events with residual deficits.
• Severe comorbidities, including active infections, known active HBV/HCV, HIV infection, uncontrolled diabetes, or serious conditions like chronic restrictive lung disease or cirrhosis.
• Known intolerance to Siltuximab.
• Known central nervous system (CNS) involement.